Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Nancy Sajjadi"'
Autor:
Janice Callahan, Nancy Sajjadi
Publikováno v:
BioProcessing Journal. 19
Autor:
Nancy Sajjadi, Janice Callahan
Publikováno v:
BioProcessing Journal. 2:83-87
Autor:
Margaret V. Ragni, Thomas E. Moon, Veronica Cole, Deborah Hurst, Sandhya Ramanathan-Girish, Jeanne M. Lusher, Holger Roehl, Douglas J. Jolly, Jerry S. Powell, Nancy Sajjadi, Carol Hillman-Wiseman, Gilbert C. White
Publikováno v:
Blood. 102:2038-2045
In a phase 1 dose escalation study, 13 subjects with hemophilia A received by peripheral intravenous infusion a retroviral vector carrying a B-domain–deleted human factor VIII (hFVIII) gene. Infusions were well tolerated. Tests for replication comp
Autor:
Janice Callahan, Nancy Sajjadi
Publikováno v:
BioProcessing Journal. 2:71-77
Autor:
James E. McCormack, Nancy Sajjadi, Thomas W. Dubensky, James G. Respess, Joanne O'Dea, Trung K. Phuong, Carlos E. Ibanez, Judith Greengard, Philip Lee Sheridan, Margaret Dow Moore, Daniel J. de la Vega, Sybille L. Sauter, Kay Townsend, Kathy Nguyen, David A. Driver, Douglas J. Jolly, Andrea Lynn, Nicholas J. DePolo, Mordechai Bodner, Stephen M. W. Chang
Publikováno v:
Molecular Therapy. 2(3):262-275
For many applications, human clinical therapies using retroviral vectors still require many technological improvements in key areas of vector design and production. These improvements include higher unprocessed manufacturing titers, complement-resist
Autor:
Nancy Sajjadi
Publikováno v:
The Quality Assurance Journal. 2:113-117
Autor:
Nancy Sajjadi, Tammi Howard, Wilson Edwards, Doug J. Jolly, Edgar Kamantigue, Steven Mento, Sunil Chada
Publikováno v:
Human Gene Therapy. 5:693-699
A murine retroviral vector encoding the human immunodeficiency virus type 1 (HIV-1) env and rev genes can be used to induce cytotoxic T lymphocyte responses. Immune responses can be induced by an ex vivo treatment, in which autologous cells are trans
Autor:
Estuardo Aguilar-Cordova, Sally S. Seaver, Steven R. Bauer, Nancy Sajjadi, Stephanie Simek, Beth Hutchins, Alasdair Shepherd, Keith Carson
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 2(6)
*Canji, Inc., San Diego, California 92121 †Consultant, Encinitas, California 92024 ‡U.S. Pharmacopeia Cell Therapy, Gene Therapy, and Tissue Engineering Expert Committee/Seaver Associates, Concord, Massachusetts 01742 §Q-One Biotech, Worcester,
Autor:
Dale E. Johnson, William G. Glass, Judith Greengard, Martin Giedlin, Edgar Kamantigue, Martha E. I. Leibbrandt, Kim Boekelheide, Douglas J. Jolly, Nancy Sajjadi, Holger Roehl
Publikováno v:
Human gene therapy. 11(18)
In a phase 1 clinical trial, we are evaluating a murine leukemia virus (MuLV)-based retroviral vector encoding the human factor VIII gene [hFVIII(V)], administered intravenously, as a therapy for hemophilia A. Preclinical biolocalization studies in a
Autor:
Nicholas J. DePolo, Darlene Martineau, Leila Akbarian, Michael J. Irwin, Stephanie Maifert, Nancy Sajjadi, John F. Warner, Kay Townsend, Will Lee, James E. McCormack, Douglas J. Jolly
Publikováno v:
Human gene therapy. 8(10)
Replication-incompetent retroviruses have been employed as gene therapy vectors in experimental settings for more than a decade. More recently, these vectors have been tested in the clinic as immunotherapeutic agents and anticancer agents. One potent